Files
Document type
ArticleVersion
Published versionPublication date
Publication license
Please use this identifier to cite or link to this item: https://hdl.handle.net/2445/158439
Insulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells
Journal Title
Director/Tutor
Additional contribution
Journal ISSN
Volume Title
Abstract
This study investigates in murine and human adipocytes the antilipolytic properties of a conjugate of benzylamine and decavanadate (B6V10), already reported to lower hyperglycaemia in diabetic rodents. Data indicated that the conjugate dose-dependently inhibited submaximal activation of lipolysis in all the species studied. Such antilipolytic action deals with the in vivo FFA-lowering properties already described for B6V10 in diabetic rats. B6V10 also activated lipogenesis and glucose transport in fat cells. B6V10 should therefore be useful in preventing the lipotoxicity constituted by the unrestrained lipolytic activity of insulin-resistant adipocytes in obese individuals presenting type 2 diabetes, a state named diabesity.
Related resource
Subject (English)
Citation
Citation
CARPÉNÉ, Christian, et al. Insulin-mimetic compound hexaquis (benzylammonium) decavanadate is antilipolytic in human fat cells. World Journal of Diabetes. 2017. Vol. 8, num. 4, pags. 143-153. ISSN 1948-9358. [consulted: 8 of October of 2026]. Available at: https://hdl.handle.net/2445/158439